Cytokine and T cell responses in post-chikungunya viral arthritis: A cross-sectional study

PLoS One. 2024 Mar 20;19(3):e0299521. doi: 10.1371/journal.pone.0299521. eCollection 2024.

Abstract

Objective: To define the relationship between chronic chikungunya post-viral arthritis disease severity, cytokine response and T cell subsets in order to identify potential targets for therapy.

Methods: Participants with chikungunya arthritis were recruited from Colombia from 2019-2021. Arthritis disease severity was quantified using the Disease Activity Score-28 and an Arthritis-Flare Questionnaire adapted for chikungunya arthritis. Plasma cytokine concentrations (interleukin (IL)-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, interferon-γ and tumor necrosis factor (TNF)) were measured using a Meso Scale Diagnostics assay. Peripheral blood T cell subsets were measured using flow cytometry.

Results: Among participants with chikungunya arthritis (N = 158), IL-2 levels and frequency of regulatory T cells (Tregs) were low. Increased arthritis disease activity was associated with higher levels of inflammatory cytokines (IL-6, TNF and CRP) and immunoregulatory cytokine IL-10 (p<0.05). Increased arthritis flare activity was associated with higher Treg frequencies (p<0.05) without affecting T effector (Teff) frequencies, Treg/Teff ratios and Treg subsets. Finally, elevated levels of IL-2 were correlated with increased Treg frequency, percent Tregs out of CD4+ T cells, and Treg subsets expressing immunosuppressive markers, while also correlating with an increased percent Teff out of live lymphocytes (p<0.05).

Conclusion: Chikungunya arthritis is characterized by increased inflammatory cytokines and deficient IL-2 and Treg responses. Greater levels of IL-2 were associated with improved Treg numbers and immunosuppressive markers. Future research may consider targeting these pathways for therapy.

MeSH terms

  • Arthritis, Infectious*
  • CD4-Positive T-Lymphocytes / metabolism
  • Chikungunya Fever* / complications
  • Cross-Sectional Studies
  • Cytokines / metabolism
  • Humans
  • Immunosuppressive Agents
  • Interleukin-10 / metabolism
  • Interleukin-2 / metabolism
  • Interleukin-6 / metabolism
  • T-Lymphocytes, Regulatory / metabolism
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Cytokines
  • Interleukin-10
  • Interleukin-2
  • Interleukin-6
  • Tumor Necrosis Factor-alpha
  • Immunosuppressive Agents

Grants and funding

Research reported in this publication was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Number K23AR076505 (niams.nih.gov) and the Pharmaceutical Research and Manufacturers of America Foundation (PhRMA) (www.phrmafoundation.org) Research Starter Grant in Translational Medicine and Therapeutics to AYC. The content is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health nor the PhRMA Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.